Hoenle AG

Hoenle AG's capital structure shows a debt-to-equity ratio of 0.63, indicating moderate leverage, while its liquidity position is characterized by a current ratio of 1.8, suggesting adequate short-term liquidity. The company's price-to-book ratio of 0.74 implies that the market values the company below its book value, which may reflect concerns about asset quality or future earnings potential. Profitability metrics reveal a challenging financial position, with a negative return on equity of -4.12% and a return on assets of -2.18%, both significantly below industry norms. The company reported a net loss of EUR 3.17 million, despite a gross profit of EUR 58.66 million, indicating high operating expenses or cost pressures. The company's revenue is distributed across three business units: Adhesive Systems, Curing, and Disinfection. While the input data does not specify the exact revenue contribution of each segment, the global presence with 20 subsidiaries suggests a diversified geographic footprint. However, the lack of detailed segmental revenue data limits the ability to assess concentration risk. Looking ahead, the company's growth trajectory is uncertain. The current fiscal year outlook does not provide specific revenue growth projections, but the negative net income and low operating income of EUR 108,000 suggest operational challenges. The company's free cash flow of EUR 306,000 is minimal, which may constrain its ability to invest in growth initiatives. Risk factors include liquidity concerns, as the company's net cash position is negative after accounting for total debt. The risk assessment indicates a medium liquidity risk and a low dilution risk, with no immediate pressure for equity issuance. The company's capital expenditure of EUR -1.9 million suggests a reduction in investment, which could impact long-term growth. Recent events and filings do not provide specific details on new product launches or strategic initiatives. The company's financial performance and operational efficiency are under scrutiny, as reflected in the analyst price targets ranging from EUR 15.00 to EUR 20.00, with a mean recommendation of 1.67, indicating a generally positive outlook from analysts.